Commentary
According to this article by D. Pfister et al. (German Cancer Research Center, Germany), the response to immunotherapy is better in patients with virus-induced HCC than in patients with non-viral HCC (that is, NASH). This might be due to the amount or quality of viral antigens or to a different liver micro-environment, possibly one that does not impair immune surveillance.
“These results might also have implications for patients with obesity and NALFD or NASH who have cancer at other organ sites”.
